NCT02992132 - Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 25, 2018

Study Completion Date

February 16, 2018

Conditions

Agitation and Aggression in Alzheimer's Disease

Interventions

DRUG

Pimavanserin 34 mg

Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth

DRUG

Pimavanserin 20 mg

Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth

OTHER

Placebo

Placebo, taken as two tablets, once daily by mouth

Trial Locations (56)

14011

Córdoba

19046

Jenkintown

19090

Willow Grove

19401

Norristown

20007

Washington D.C.

28044

Madrid

28270

Charlotte

29401

Charleston

30322

Atlanta

31014

Pamplona

31059

Toulouse

33064

Deerfield Beach

33137

Miami

33486

Boca Raton

34102

Naples

37212

Nashville

39216

Jackson

39232

Flowood

44800

Saint-Herblain

48035

Clinton Township

48993

Algorta

50012

Zaragoza

67200

Strasbourg

69100

Villeurbanne

73112

Oklahoma City

75010

Paris

75115

DeSoto

84124

Salt Lake City

87131

Albuquerque

90073

Los Angeles

91105

Pasadena

92103

San Diego

92626

Costa Mesa

92835

Fullerton

93710

Fresno

97504

Medford

99202

Spokane

1270244

Antofagasta

5090000

Valdivia

7500710

Santiago

7560356

Santiago

06810

Danbury

04401

Bangor

02169

Quincy

07724

Eatontown

08053

Marlton

08755

Toms River

03203

Elche

07010

Palma de Mallorca

08921

Santa Coloma de Gramenet

08221

Terrassa

SN3 6BW

Swindon

BA1 3NG

Bath

TW7 6AF

Isleworth

M21 9UN

Manchester

NN5 6UD

Northampton